LPCN
Lipocine Inc.
There isn't enough reported data to score LPCN yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
LPCN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Unavailable | |
| Unavailable |
LPCN's revenue is currently stable, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
LPCN PE Valuation
LPCN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
LPCN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect LPCN's losses to shrink, with revenue declining.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LPCN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.28 | -$0.27 |
| Q2 2026 | -$1.79 | -$0.93 |
| Q1 2026 | -$1.88 | -$0.87 |
| Q4 2025 | -$1.69 | -$1.69 |
| Q3 2025 | -$1.01 | +$0.48 |
| Q2 2025 | -$0.86 | +$1.45 |
| Q1 2025 | -$1.01 | +$1.42 |
| Q4 2024 | -$0.00 | +$3.77 |
LPCN is still losing money, but far less than before: $1.28 per share over the past year, against $8.50 at its worst in late 2019.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over LPCN on earnings quality, reporting a profit while its opponent remains loss making.
LPCN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.3M | +1899% |
| Q2 2026 | $190.1K | -69% |
| Q1 2026 | $119.4K | +27% |
| Q4 2025 | $1.1M | -67% |
| Q2 2025 | $622.8K | +595% |
| Q1 2025 | $93.9K | -99% |
| Q4 2024 | $3.5M | +1515% |
| Q1 2024 | $7.6M | +13752% |
LPCN's revenue is recovering but still below its 2021 peak: $2M last quarter, up 1899% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -38% | +2896 points |
| Q2 2026 | -1495% | -1109 points |
| Q1 2026 | -3224% | -997 points |
| Q4 2025 | -220% | -264 points |
| Q3 2025 | -2934% | N/A |
| Q2 2025 | -386% | +3290 points |
| Q1 2025 | -2227% | -2269 points |
| Q4 2024 | 44% | +1244 points |
LPCN's operating margin was −38% last quarter, up 2896 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over LPCN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over LPCN on profitability, with a higher operating margin.
LPCN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3M | -$1.1M |
| Q1 2026 | -$2.3M | -$287.9K |
| Q4 2024 | $1.7M | +$3.7M |
| Q4 2023 | -$2M | -$95.8K |
| Q3 2023 | -$2.6M | +$592.1K |
| Q2 2023 | -$3.3M | -$253K |
| Q1 2023 | -$3.9M | -$19.9K |
| Q3 2022 | -$3.2M | +$3.8M |
LPCN has the stronger cash trend. Its trailing FCF is up 26% versus its history, compared with UNH at up 5.2%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
LPCN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +27.6K shares |
| 1 year | +54% | +2.9M shares |
| 3 years | +57% | +3M shares |
| 5 years | +59% | +3.1M shares |
| Available history | +239% | +5.8M shares |
LPCN has 8M diluted shares, up 54% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2023 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over LPCN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
LPCN Net Leverage
LPCN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
LPCN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.9 | Neutral |
| Stochastic | 9.5 | Oversold |
LPCN's weekly RSI is 35 (neutral) and its Stochastic is 10 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
LPCN PE vs Healthcare Sector
| Metric | LPCN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LPCN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
LPCN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.69 | 4.1% below |
| 20 week MA | $2.01 | 19% below |
| 50 week MA | $3.99 | 59% below |
| 100 week MA | $3.69 | 56% below |
| 200 week MA | $4.28 | 62% below |
LPCN is in a downtrend: it's below all five of its weekly moving averages, and 62% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over LPCN on trend strength, trading above more of its moving averages.
LPCN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.04 | $24.1 | +300% |
| 2021 | $24.1 | $18.0 | -25% |
| 2022 | $18.0 | $6.90 | -62% |
| 2023 | $6.90 | $2.79 | -60% |
| 2024 | $2.79 | $4.76 | +71% |
| 2025 | $4.76 | $5.23 | +9.9% |
| 2026 YTD | $5.23 | $1.62 | -69% |
LPCN's yearly returns have swung widely, from +300% in 2020 to −62% in 2022. It's down 69% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over LPCN on returns for 2026, with the stronger performance.